Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the framingham heart study. Circulation. 2004;110:522–7.
de Bruyne MC, Hoes AW, Kors JA, Hofman A, van Bemmel JH, Grobbee DE. QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. Circulation. 1998;97:467–72.
Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation. 1978;57:1074–7.
Dekker JM, Crow RS, Hannan PJ, Schouten EG, Folsom AR, ARIC Study. Heart rate-corrected QT interval prolongation predicts risk of coronary heart disease in black and white middle-aged men and women: The ARIC study. J Am Coll Cardiol. 2004;43:565–71.
Robbins J, Nelson JC, Rautaharju PM, Gottdiener JS. The association between the length of the QT interval and mortality in the cardiovascular health study. Am J Med. 2003;115:689–94.
Im SW, Lee MK, Lee HJ, Oh SI, Kim HL, Sung J, et al. Analysis of genetic and non-genetic factors that affect the QTc interval in a Mongolian population: the GENDISCAN study. Exp Mol Med. 2009;41:841–8.
Busjahn A, Knoblauch H, Faulhaber HD, Boeckel T, Rosenthal M, Uhlmann R, et al. QT interval is linked to 2 long-QT syndrome loci in normal subjects. Circulation. 1999;99:3161–4.
Nie Y, Zou J, Liang Y, Shen B, Liu Z, Cao X, et al. Electrocardiographic abnormalities and QTc interval in patients undergoing hemodialysis. PLoS One. 2016;11:e0155445.
Tbahriti HF, Meknassi D, Moussaoui R, Messaoudi A, Zemour L, Kaddous A, et al. Inflammatory status in chronic renal failure: the role of homocysteinemia and pro-inflammatory cytokines. World J Nephrol. 2013;2:31–7.
Jara A, Mezzano S. Vascular damage in chronic kidney disease. Rev Med Chil. 2008;136:1476–84.
Hoffman BF, Feinmark SJ, Guo SD. Electrophysiologic effects of interactions between activated canine neutrophils and cardiac myocytes. J Cardiovasc Electrophysiol. 1997;8:679–87.
Hoffman BF, Guo SD, Feinmark SJ. Arrhythmias caused by platelet activating factor. J Cardiovasc Electrophysiol. 1996;7:120–33.
Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886–91.
Parekh RS, Plantinga LC, Kao WH, Meoni LA, Jaar BG, Fink NE, et al. The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int. 2008;74:1335–42.
Makowski L, Hotamisligil GS. Fatty acid binding proteins-the evolutionary crossroads of inflammatory and metabolic responses. J Nutr. 2004;134:2464S–8S.
Stejskal D, Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome? Eur J Clin Investig. 2006;36:621–5.
Bagheri R, Qasim AN, Mehta NN, Terembula K, Kapoor S, Braunstein S, et al. Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. Am J Cardiol. 2010;106:1118–23.
Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006;52:405–13.
Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 2007;115:1537–43.
Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, Schunck WH, et al. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res. 2009;105:326–34.
Tso AW, Lam TK, Xu A, Yiu KH, Tse HF, Li LS, et al. Serum adipocyte fatty acid-binding protein associated with ischemic stroke and early death. Neurology. 2011;76:1968–75.
Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care. 2007;30:2667–72.
Miyoshi T, Onoue G, Hirohata A, Hirohata S, Usui S, Hina K, et al. Serum adipocyte fatty acid- binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis. 2010;211:164–9.
Jin J, Peng DQ, Yuan SG, Zhao SP, Ning XH, Wang SH, et al. Serum adipocyte fatty acid binding proteins and adiponectin in patients with coronary artery disease: the significance of A-FABP/ adiponectin ratio. Clin Chim Acta. 2010;411:1761–5.
Djoussé L, Bartz TM, Ix JH, Kochar J, Kizer JR, Gottdiener JS, et al. Fatty acid-binding protein 4 and incident heart failure: the cardiovascular health Study. Eur J Heart Fail. 2013;15:394–9.
Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, Plana N, et al. Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. Clin Chem. 2008;54:181–7.
Kong X, Ma Y, Chen J, Luo Q, Yu X, Li Y, et al. Chinese eGFR investigation collaboration. Evaluation of the chronic kidney disease epidemiology collaboration equation for estimating glomerular filtration rate in the Chinese population. Nephrol Dial Transplant. 2013;28:641–51.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl 1):S64–71.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97.
Gensini GG. Amore meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606.
Wang CP, Hsu HL, Hung WC, Yu TH, Chen YH, Chiu CA, et al. Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis. Clin Endocrinol. 2009;70:876–82.
Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009;53:982–91.
Naksuk N, Hu T, Krittanawong C, Thongprayoon C, Sharma S, Park JY, et al. Association of Serum Magnesium on mortality in patients admitted to the intensive cardiac care Unit. Am J Med. 2017;130:229.e5–229.e13.
Salvi V, Karnad DR, Panicker GK, Natekar M, Hingorani P, Kerkar V, et al. Comparison of 5 methods of QT interval measurements on electrocardiograms from a thorough QT/QTc study: effect on assay sensitivity and categorical outliers. J Electrocardiol. 2011;44:96–104.
Malik M, Hnatkova K, Batchvarov V, Gang Y, Smetana P, Camm AJ. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Pacing Clin Electrophysiol. 2004;27:1659–69.
Straus SM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47:362–7.
Sano K, Watanabe E, Hayano J, Mieno Y, Sobue Y, Yamamoto M, et al. Central sleep apnoea and inflammation are independently associated with arrhythmia in patients with heart failure. Eur J Heart Fail. 2013;15:1003–10.
Vasilets LM, Tuev AV, Agafonov AV, Ratanova EA, Krivaia AA, Trenogina KV, et al. Ventricular arrhythmias and arterial hypertension: role of inflammatory biomarkers in arrhythmia development. Vestn Ross Akad Med Nauk. 2012;10:12–7.
Bernlohr DA, Bolanowski MA, Kelly TJ Jr, Lane MD. Evidence for an increase in transcription of specific mRNAs during differentiation of 3T3-L1 preadipocytes. J Biol Chem. 1985;260:5563–7.
Bernlohr DA, Doering TL, Kelly TJ Jr, Lane MD. Tissue specific expression of p422 protein, a putative lipid carrier, in mouse adipocytes. Biochem Biophys Res Commun. 1985;132:850–5.
Yang VW, Christy RJ, Cook JS, Kelly TJ, Lane MD. Mechanism of regulation of the 422(aP2) gene by cAMP during preadipocyte differentiation. Proc Natl Acad Sci U S A. 1989;86:3629–33.
Wang XQ, Yang K, He YS, Lu L, Shen WF. Receptor mediated elevation in FABP4 levels by advanced glycation end products induces cholesterol and triacylglycerol accumulation in THP-1 macrophages. Lipids. 2011;46:479–86.
Kazemi MR, McDonald CM, Shigenaga JK, Grunfeld C, Feingold KR. Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler Thromb Vasc Biol. 2005;25:1220–4.
Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem. 2005;280:12888–95.
Hui X, Li H, Zhou Z, Lam KS, Xiao Y, Wu D, et al. Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J Biol Chem. 2010;285:10273–80.
Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, et al. Lack of macrophage fatty-acidbinding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med. 2001;7:699–705.
Rodríguez-Calvo R, Girona J, Alegret JM, Bosquet A, Ibarretxe D, Masana L. Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. J Endocrinol. 2017;233:R173–R84.
Bignotto LH, Kallás ME, Djouki RJ, Sassaki MM, Voss GO, Soto CL, et al. Electrocardiographic findings in chronic hemodialysis patients. J Bras Nefrol. 2012;34:235–42.
Vianna HR, Soares CM, Tavares MS, Teixeira MM, Silva AC. Inflammation in chronic kidney disease: the role of cytokines. J Bras Nefrol. 2011;33:351–64.
Shamseddin MK, Parfrey PS. Mechanisms of the cardiorenal syndromes. Nat Rev Nephrol. 2009;5:641–9.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.
Furuhashi M, Ishimura S, Ota H, Hayashi M, Nishitani T, Tanaka M, et al. Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One. 2011;6:e27356.
Furuhashi M, Fucho R, Görgün CZ, Tuncman G, Cao H, Hotamisligil GS. Adipocyte/ macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest. 2008;118:2640–50.
Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, et al. Adipocyte/ macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab. 2005;1:107–19.
Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 2004;110:1492–8.
Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, Mozaffarian D. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2013;98:160–73.
Adamopoulos C, Pitt B, Sui X, Love TE, Zannad F, Ahmed A. Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study. Int J Cardiol. 2009;136:270–7.